<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2658-6533-2022-8-1-0-7</article-id><article-id pub-id-type="publisher-id">2673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine (miscellaneous)</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Gastrointestinal stromal tumors in elderly patients&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Gastrointestinal stromal tumors in elderly patients&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Polyanskiy</surname><given-names>Maksim B.</given-names></name><name xml:lang="en"><surname>Polyanskiy</surname><given-names>Maksim B.</given-names></name></name-alternatives><email>polyanscky.maks@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Zvyagin</surname><given-names>Ivan N.</given-names></name><name xml:lang="en"><surname>Zvyagin</surname><given-names>Ivan N.</given-names></name></name-alternatives><email>dr.zvyagin@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Dronov</surname><given-names>Sergey P.</given-names></name><name xml:lang="en"><surname>Dronov</surname><given-names>Sergey P.</given-names></name></name-alternatives><email>s.p.dronov@gmail.com</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Rukavishnikov</surname><given-names>Aleksey S.</given-names></name><name xml:lang="en"><surname>Rukavishnikov</surname><given-names>Aleksey S.</given-names></name></name-alternatives><email>9041623asr@gmail.com</email></contrib></contrib-group><pub-date pub-type="epub"><year>2022</year></pub-date><volume>8</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2022/1/Биомедицинские_исследования-92-106.pdf" /><abstract xml:lang="ru"><p>Background: Gastrointestinal stromal tumors (GISTs) account for 1 to 3% of all primary malignant tumors of the gastrointestinal tract. The global incidence of GISTs varies in the range of 7-15 cases per 1 million people per year. In about 95% of cases, the incidence is sporadic. Despite the fact that some success has been achieved in the treatment of this pathology, the problem of GISTs treatment is urgent, especially in elderly and senile patients in particular. The aim of the study: To study the age-related characteristics of GISTs development in patients of older age groups. Materials and methods: A retrospective analysis of 56 clinical cases of GISTs in patients of different age groups according to the WHO classification was carried out in the study. Results: The most common variant of the immunohistochemical structure was the spindle cell one &amp;ndash; 62.5%. In most cases, tumors were localized in the stomach &amp;ndash; 82.2%. Elderly patients had larger tumor sizes compared with young and middle-aged patients. In patients of older age groups, the disease was most often detected at stage II. In most cases, a comorbid pathology was detected, most often a combination of several diseases of the cardiovascular system. Conclusion: In patients of older age groups, the spindle cell structure of the GISTs is most common, the tumor was most often localized in the stomach (77.4%), most often the tumor was localized along the lesser curvature. In most cases, the tumor was up to 10.0 cm in diameter. On average, the disease was detected at stage II. Comorbid pathology occurred in 87.3% of cases. In 2020-2021, the disease was detected more often, the of tumors sizes were smaller, due to an increase in the number of CT scans of the chest for the diagnosis of the new coronavirus infection.</p></abstract><trans-abstract xml:lang="en"><p>Background: Gastrointestinal stromal tumors (GISTs) account for 1 to 3% of all primary malignant tumors of the gastrointestinal tract. The global incidence of GISTs varies in the range of 7-15 cases per 1 million people per year. In about 95% of cases, the incidence is sporadic. Despite the fact that some success has been achieved in the treatment of this pathology, the problem of GISTs treatment is urgent, especially in elderly and senile patients in particular. The aim of the study: To study the age-related characteristics of GISTs development in patients of older age groups. Materials and methods: A retrospective analysis of 56 clinical cases of GISTs in patients of different age groups according to the WHO classification was carried out in the study. Results: The most common variant of the immunohistochemical structure was the spindle cell one &amp;ndash; 62.5%. In most cases, tumors were localized in the stomach &amp;ndash; 82.2%. Elderly patients had larger tumor sizes compared with young and middle-aged patients. In patients of older age groups, the disease was most often detected at stage II. In most cases, a comorbid pathology was detected, most often a combination of several diseases of the cardiovascular system. Conclusion: In patients of older age groups, the spindle cell structure of the GISTs is most common, the tumor was most often localized in the stomach (77.4%), most often the tumor was localized along the lesser curvature. In most cases, the tumor was up to 10.0 cm in diameter. On average, the disease was detected at stage II. Comorbid pathology occurred in 87.3% of cases. In 2020-2021, the disease was detected more often, the of tumors sizes were smaller, due to an increase in the number of CT scans of the chest for the diagnosis of the new coronavirus infection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>GISTs</kwd><kwd>cells of Cajal</kwd><kwd>elderly patients</kwd><kwd>oncologic pathology</kwd><kwd>immunohistochemical structure</kwd><kwd>mitotic index</kwd></kwd-group><kwd-group xml:lang="en"><kwd>GISTs</kwd><kwd>cells of Cajal</kwd><kwd>elderly patients</kwd><kwd>oncologic pathology</kwd><kwd>immunohistochemical structure</kwd><kwd>mitotic index</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases. American Journal of Surgical Pathology. 2009;33(9):1267-1275. DOI: https://doi.org/10.1097/PAS.0b013e3181a13e99</mixed-citation></ref><ref id="B2"><mixed-citation>Burch J, Ahmad I.&amp;nbsp;&amp;nbsp;Gastrointestinal Stromal Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [cited 2021 Oct 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554541/</mixed-citation></ref><ref id="B3"><mixed-citation>Schaefer IM, Wang Y, Liang CW, et al. MAX inactivation is an early event in GISTs development that regulates p16 and cell proliferation. Nature Communications. 2017;8:14674. DOI: https://doi.org/10.1038/ncomms14674</mixed-citation></ref><ref id="B4"><mixed-citation>Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. International Journal of Surgical Pathology. 2002;10(2):81-89. DOI: https://doi.org/10.1177/106689690201000201</mixed-citation></ref><ref id="B5"><mixed-citation>Kapatia G, Gupta N, Saikia UN, et al. Fine needle aspiration cytology of primary and metastatic gastrointestinal stromal tumour. Cytopathology. 2020;31(2):136-143. DOI: https://doi.org/10.1111/cyt.12785</mixed-citation></ref><ref id="B6"><mixed-citation>F&amp;uuml;l&amp;ouml;p E, Marcu S, Milutin D, et al. Gastrointestinal stromal tumors: Review on morphology, diagnosis and management. Romanian Journal of Morphology and Embryology. 2009;50(3):319-326.</mixed-citation></ref><ref id="B7"><mixed-citation>Van der Graaf WTA, Tielen R, Bonenkamp JJ, et al. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. British Journal of Surgery. 2018;105(8):1020-1027. DOI: https://doi.org/10.1002/bjs.10809</mixed-citation></ref><ref id="B8"><mixed-citation>Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: Results of a population-based study. Cancer Epidemiology Biomarkers and Prevention. 2015;24(1):298-302. DOI: https://doi.org/10.1158/1055-9965.EPI-14-1002</mixed-citation></ref><ref id="B9"><mixed-citation>Gopie P, Mei L, Faber AC, et al. Classification of gastrointestinal stromal tumor syndromes. Endocrine-Related Cancer. 2018;25(2):49-58. DOI: https://doi.org/10.1530/ERC-17-0329</mixed-citation></ref><ref id="B10"><mixed-citation>Gasparotto D, Rossi S, Polano M, et al. Quadruple-Negative GISTs Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. Clinical Cancer Research 2017;23(1):273-282. DOI: https://doi.org/10.1158/1078-0432.CCR-16-0152</mixed-citation></ref><ref id="B11"><mixed-citation>Nannini M, Urbini M, Astolf A, et al. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GISTs). Journal of Translational Medicine. 2017;15:113. DOI: https://doi.org/10.1186/s12967-017-1212-x</mixed-citation></ref><ref id="B12"><mixed-citation>оreidea K, Sandvika OM, Sоreidea JA, et al. Global epidemiology of gastrointestinal stromal tumours (GISTs): A systematic review of population-based cohort studies. Cancer Epidemiology. 2016;40:39-46. DOI: https://doi.org/10.1016/j.canep.2015.10.031</mixed-citation></ref><ref id="B13"><mixed-citation>Neppala P, Banerjee S, Fanta PT, et al. Current Management of Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors. Cancer and Metastasis Reviews. 2019;38:525-535. DOI: https://doi.org/10.1007/s10555-019-09818-0</mixed-citation></ref><ref id="B14"><mixed-citation>Mason EF, Hornick JL. Conventional Risk Stratification Fails to Predict Progression of Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors: A Clinicopathologic Study of 76 Cases. American Journal of Surgical Pathology. 2016;40(12):1616-1621. DOI: https://doi.org/10.1097/PAS.0000000000000685</mixed-citation></ref><ref id="B15"><mixed-citation>Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. 2016;27(9):1794-1799. DOI: https://doi.org/10.1093/annonc/mdw228</mixed-citation></ref><ref id="B16"><mixed-citation>American Society of Clinical Oncology [Internet]. [cited 2021 Oct 20]. Available from:&amp;nbsp;https://www.cancer.net/.</mixed-citation></ref><ref id="B17"><mixed-citation>Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. The Lancet. 2013;382(9896):973-983. DOI: https://doi.org/10.1016/S0140-6736(13)60106-3</mixed-citation></ref><ref id="B18"><mixed-citation>van Roggen JFG, van Velthuysen MLF, Hogendoorn PCW. The histopathological differential diagnosis of gastrointestinal stromal tumours. Journal of Clinical Pathology. 2001;54:96-102. DOI: http://dx.doi.org/10.1136/jcp.54.2.96</mixed-citation></ref></ref-list></back></article>